Stay updated on Azacitidine + Pembrolizumab in AML Clinical Trial

Sign up to get notified when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Azacitidine + Pembrolizumab in AML Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    Site revision label updated from v3.4.2 to v3.4.3 in the page header/footer.
    Difference
    0.1%
    Check dated 2026-03-07T20:41:18.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    20 days ago
    No Change Detected
  4. Check
    27 days ago
    Change Detected
    Summary
    Revision: v3.4.2 was applied, replacing the previous v3.4.1. No substantive study information or user-facing content was changed.
    Difference
    0.1%
    Check dated 2026-02-14T05:05:24.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Page revision updated from v3.4.0 to v3.4.1, which does not alter the study details, inclusion criteria, or outcome measures. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2026-02-06T23:32:17.000Z thumbnail image
  6. Check
    48 days ago
    Change Detected
    Summary
    Minor UI/text updates: Show glossary and Hide glossary controls were added, along with a new 'Last Update Submitted that Met QC Criteria' label and a Revision: v3.4.0 tag. Wording and capitalization tweaks were made to 'No FEAR Act Data' and 'Last Update Submitted that met QC Criteria'.
    Difference
    0.3%
    Check dated 2026-01-23T11:00:49.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    Revision: v3.3.4 was added and the previous Revision: v3.3.3 was removed.
    Difference
    0.1%
    Check dated 2026-01-16T07:38:52.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    A new Locations section lists Maryland, North Carolina, and South Carolina, replacing the previous individual location entries. The HHS Vulnerability Disclosure link has been removed, and the page revision updated from v3.3.2 to v3.3.3.
    Difference
    0.4%
    Check dated 2025-12-18T21:09:01.000Z thumbnail image

Stay in the know with updates to Azacitidine + Pembrolizumab in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Azacitidine + Pembrolizumab in AML Clinical Trial page.